Literature DB >> 9124861

Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.

R W Shafer1, M A Winters, A K Iversen, T C Merigan.   

Abstract

The observation that human immunodeficiency virus type 1 (HIV-1) mutations conferring resistance to one reverse transcriptase (RT) inhibitor may suppress resistance to other RT inhibitors provides a rationale for treating HIV-1 with certain RT inhibitor combinations. We examined phenotypic and genotypic changes during culture of a multinucleoside (zidovudine, didanosine, zalcitibine, and stavudine)-resistant HIV-1 strain with and without additional RT inhibitors (nevirapine and lamivudine). The development of nevirapine or lamivudine resistance by the multinucleoside-resistant strain was not accompanied by a reduction in zidovudine or didanosine resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124861      PMCID: PMC163642     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Authors:  D Richman; C K Shih; I Lowy; J Rose; P Prodanovich; S Goff; J Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.

Authors:  J C Schmit; J Cogniaux; P Hermans; C Van Vaeck; S Sprecher; B Van Remoortel; M Witvrouw; J Balzarini; J Desmyter; E De Clercq; A M Vandamme
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

4.  Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction.

Authors:  M Nijhuis; C A Boucher; R Schuurman
Journal:  Biotechniques       Date:  1995-08       Impact factor: 1.993

5.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

6.  Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.

Authors:  B A Larder; A Kohli; S Bloor; S D Kemp; P R Harrigan; R T Schooley; J M Lange; K N Pennington; M H St Clair
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.

Authors:  J J Eron; S L Benoit; J Jemsek; R D MacArthur; J Santana; J B Quinn; D R Kuritzkes; M A Fallon; M Rubin
Journal:  N Engl J Med       Date:  1995-12-21       Impact factor: 91.245

8.  Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates.

Authors:  T Ueno; T Shirasaka; H Mitsuya
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

9.  Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.

Authors:  Z Gu; Q Gao; X Li; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.

Authors:  A K Iversen; R W Shafer; K Wehrly; M A Winters; J I Mullins; B Chesebro; T C Merigan
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more
  5 in total

1.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

2.  Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.

Authors:  R W Shafer; J A Eisen; T C Merigan; D A Katzenstein
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors.

Authors:  M A Winters; K L Coolley; P Cheng; Y A Girard; H Hamdan; L C Kovari; T C Merigan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

5.  The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.

Authors:  Jean L Mbisa; Ravi K Gupta; Desire Kabamba; Veronica Mulenga; Moxmalama Kalumbi; Chifumbe Chintu; Chris M Parry; Diana M Gibb; Sarah A Walker; Patricia A Cane; Deenan Pillay
Journal:  Retrovirology       Date:  2011-05-11       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.